Pegaspargase

Product Description

A drug used with other drugs to treat adults and children with acute lymphoblastic leukemia. It is used in patients whose cancer has not already been treated or who cannot be treated with asparaginase. It is also being studied in the treatment of other types of cancer. Pegaspargase is made up of the enzyme L-asparaginase that is linked to a substance called PEG, which makes the drug stay in the body longer. L-asparaginase comes from the bacterium E. coli and breaks down the amino acid asparagine. This may stop the growth of cancer cells that need asparagine to grow. Pegaspargase is a type of protein synthesis inhibitor. Also called Oncaspar and PEG-asparaginase. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pegaspargase)

Mechanisms of Action: TK Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intramuscular,Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay

Approved Indications: Acute Leukemia | Acute Lymphoid Leukemia | Leukemia | Lymphoid Leukemia

Known Adverse Events: Pancreatitis | Febrile Neutropenia | Hypoalbuminemia | Neutropenia | Hyperglycemia

Company: Shuanglu Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None